Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Hormone combination helps short teens become taller

17 Sep 2020

In teens with short stature, the combination of gonadotropin releasing hormone analogue (GnRHa) and recombinant human growth hormone (rhGH) yields a significant increase in adult height, as shown in a study.

A total of 94 adolescents with normal pubertal onset and short stature were treated with GnRHa/rhGH: 49 boys for a mean of 24.84 months and 45 girls for a mean of 23.89 months. Among them, 25 boys and 12 girls had idiopathic short stature (ISS). All participants were followed to measure their adult height.

At baseline, in boys, the height (Ht) standard deviation score (SDS) was −1.82, while the target height was 168.98 cm. In girls, the HtSDS was −1.10, and the target height was 157.90 cm. After treatment, adult height SDS increased by 1.37 (p=0.000) in boys and by 1.28 (p=0.000) in girls.

The adult height in boys was 169.96 cm, taller by 0.98 cm than the target height (p=0.273). Girls, on the other hand, gained more. Their adult height was 161.54 cm, which was 3.64-cm greater than their target height (p=0.000).

Subgroup analysis revealed that teens with ISS were able to reach their target height. In boys, although their adult height was 0.70-cm short of the target, the SDS value indicated that adult height increased by 2.00 relative to pre-treatment HtSDS (p=0.000). In girls, their adult height was greater by 2.63 cm than the target, with the SDS increasing by 2.73 vs HtSDS (p=0.000).

On the other hand, teens without ISS achieved a height that exceeded their targets. Compared with the target, adult height increased by 2.73 cm in boys and 4.02 cm in girls. The differences between adult height SDS and HtSDS were 0.71 (p=0.003) and 0.748 (p=0.001), respectively.

In multiple linear regression analysis, significant factors that negatively influenced adult height SDS increments were baseline bone age (p=0.003), basal IGF-1 (p=0.008), and HtSDS (p=0.000).

There were no serious adverse reactions reported. One child reported a transient mild headache, and two had a small rash and mild itching at the injection site. None of these symptoms resulted in treatment interruption or withdrawal. There were no incidences of bone fracture.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.